secwatch.observer — SEC 8-K summary
======================================

Issuer:     Ocugen, Inc. (OCGN)
CIK:        0001372299
Form:       8-K
Filed at:   2025-06-23T23:59:59+00:00
Accession:  0001104659-25-061435
Event type: m_and_a
Sentiment:  positive
Materiality: 0.85
Item codes: 1.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Ocugen's OrthoCellix to merge with Carisma in reverse merger; combined entity to focus on NeoCart
--------------------------------------------------------------------------------

- OrthoCellix valued at $135M; Carisma at $15M; post-merger Ocugen/investors own ~90%, Carisma holders ~10%.
- Concurrent $25M financing from Ocugen ($5M guaranteed) and other investors to fund NeoCart Phase 3 trial.
- Combined company to trade as 'OrthoCellix Inc.' on Nasdaq under ticker OCLX; closing expected H2 2025.
- NeoCart is Phase 3-ready autologous cartilage implant for knee defects; received FDA RMAT designation.
- Carisma legacy asset CVRs issued to pre-merger Carisma stockholders; termination fees of $500K-$750K if deal fails.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1372299/000110465925061435/0001104659-25-061435-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1372299/000110465925061435/tm2518642d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-061435

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer